报价延迟最少15分钟:2025/07/20 13:12 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.3899 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.08/-0.96
|
|
企业价值
501.96M
|
| 资产负债 |
|
每股账面净值
-0.89
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
9.20M
|
|
每股收益
0.11
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 13:12 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI. |
